Investor Call Transcript- FY 2025-26- Q4 Earnings/ Investor Call held on 06th May 2026
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vimta Labs reported strong Q4 FY26 results with total income of INR1,120 million (up 16.6% YoY) and EBITDA of INR421 million (up 21.5% YoY) at 37.6% margins. Full year FY26 total income was INR4,163 million (up 19.5% YoY) with EBITDA of INR1,489 million at 35.8% margins. The company maintained a net debt-free balance sheet with INR650 million cash. Management highlighted that 90% of revenues come from pharma and food testing, with pharma driven by ANDA filings and generic product releases. A new biologics contract research vertical is being launched in FY27 with infrastructure and people ready, targeting initial client onboarding from Europe, India, and US. A US subsidiary has been approved to be closer to customers. Management cited geopolitical impacts including slightly higher input costs and longer supply chain lead times affecting Q4 food testing.
Strong margin performance (35.8% EBITDA) and 19.5% revenue growth position Vimta well, though management flagged potential 1-2% margin correction due to input cost pressures while targeting 20-25% CAGR. New biologics vertical and US subsidiary represent growth opportunities but won't be significant near-term contributors.